Phase 2 study of abemaciclib (LY2835219) combination with BI 836845 in patients with HR+, HER2- metastatic breast cancer and other solid tumors

Trial Profile

Phase 2 study of abemaciclib (LY2835219) combination with BI 836845 in patients with HR+, HER2- metastatic breast cancer and other solid tumors

Planning
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2016

At a glance

  • Drugs Abemaciclib (Primary) ; Xentuzumab (Primary)
  • Indications Advanced breast cancer; Solid tumours
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 18 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top